A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer.

Erlotinib is a small molecular inhibitor of tyrosine kinase. Multiple foreign and demestic studies have confirmed that it can prolong the median progression-free survival time (PFS) and the overall survival (OS), which could be more significant in the selected population. In this study we retrospect...

Full description

Saved in:
Bibliographic Details
Published in:Zhongguo fei ai za zhi 2009-12, Vol.12 (12), p.1309-1311
Main Authors: Wu, Yuhua, Tao, Hong, Tang, Junfang, Zhang, Xinyong, Zhu, Yunzhong, Liu, Zhe, Shi, Heling, Meng, Qiyi, Wu, Wei, Liu, Zan, Guo, Lili, Li, Mingzhi, Xu, Liyan
Format: Article
Language:Chinese
Subjects:
Erlotinib
Lung neoplasms
Treatment outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 1311
container_issue 12
container_start_page 1309
container_title Zhongguo fei ai za zhi
container_volume 12
creator Wu, Yuhua
Tao, Hong
Tang, Junfang
Zhang, Xinyong
Zhu, Yunzhong
Liu, Zhe
Shi, Heling
Meng, Qiyi
Wu, Wei
Liu, Zan
Guo, Lili
Li, Mingzhi
Xu, Liyan
description Erlotinib is a small molecular inhibitor of tyrosine kinase. Multiple foreign and demestic studies have confirmed that it can prolong the median progression-free survival time (PFS) and the overall survival (OS), which could be more significant in the selected population. In this study we retrospectively oberserved the response, the survival and adverse reaction of erlotinib in non-selected non-small cell lung cancer. The retrospective study included seventy non-small-cell lung cancer patients, who were treated with erlotinib from July 2005 to July 2009. Erlotinib was prescribed at a dose of 150 mg daily. Sixty-eight patients were evaluated response. Among these patients, CR 0 case, PR 26 cases, RR (CR+PR) 38.2% and SD 24 cases as their best response, disease control rate (DCR=CR+PR+SD) 73.5%, PD 18 cases (26.5%). Sixty-three patients were evaluated PFS. The median PFS was 3.0 months. The median PFS of adenocarcinoma and non-adenocarcinoma was 3.0 months vs 2.6 months. The drug-related adverse reactions were
doi_str_mv 10.3779/j.issn.1009-3419.2009.12.18
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_eb873fc4ad1543629c012ec492eb6704</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_eb873fc4ad1543629c012ec492eb6704</doaj_id><sourcerecordid>748968872</sourcerecordid><originalsourceid>FETCH-LOGICAL-d191t-fc880b4900a85a3edbd210252d20a64c3ed1a0cd1bbd40a576ef180efb8bef473</originalsourceid><addsrcrecordid>eNo9UMtOHDEQtKKgQDb5BWSJA6cZ_NqxfUQrCEirgAg5j_zoAa9mxovtScTfYwLk0l1dXapWF0InlLRcSn22a0POc0sJ0Q0XVLesopaylqpP6IhqrZuOKvm54g_JIfqa846QjmkuvqBDRiTjXNMj5M7xHZQU8x5cCX8A_yqLf8ZxwBdpjCXMweIw4_II-D6BKRPM5XUrCb41JdQp47-hPOKfcW7yZMYRb6CW7TI_4I2ZHaT2GzoYzJjh-3tfod-XF_ebq2Z78-N6c75tPNW0NINTilihCTFqbTh46xklbM08I6YTrjLUEOeptV4Qs5YdDFQRGKyyMAjJV-j6zddHs-v3KUwmPffRhP4fEdNDb1IJboQerJJ8cMJ4uha8xuIIZeCEZmA7SUT1On3z2qf4tEAu_RSyq5-ZGeKSeymU7pSqMa7Q8btysRP4_3c_MuYvXi6AaA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>748968872</pqid></control><display><type>article</type><title>A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer.</title><source>Publicly Available Content Database</source><creator>Wu, Yuhua ; Tao, Hong ; Tang, Junfang ; Zhang, Xinyong ; Zhu, Yunzhong ; Liu, Zhe ; Shi, Heling ; Meng, Qiyi ; Wu, Wei ; Liu, Zan ; Guo, Lili ; Li, Mingzhi ; Xu, Liyan</creator><creatorcontrib>Wu, Yuhua ; Tao, Hong ; Tang, Junfang ; Zhang, Xinyong ; Zhu, Yunzhong ; Liu, Zhe ; Shi, Heling ; Meng, Qiyi ; Wu, Wei ; Liu, Zan ; Guo, Lili ; Li, Mingzhi ; Xu, Liyan</creatorcontrib><description>Erlotinib is a small molecular inhibitor of tyrosine kinase. Multiple foreign and demestic studies have confirmed that it can prolong the median progression-free survival time (PFS) and the overall survival (OS), which could be more significant in the selected population. In this study we retrospectively oberserved the response, the survival and adverse reaction of erlotinib in non-selected non-small cell lung cancer. The retrospective study included seventy non-small-cell lung cancer patients, who were treated with erlotinib from July 2005 to July 2009. Erlotinib was prescribed at a dose of 150 mg daily. Sixty-eight patients were evaluated response. Among these patients, CR 0 case, PR 26 cases, RR (CR+PR) 38.2% and SD 24 cases as their best response, disease control rate (DCR=CR+PR+SD) 73.5%, PD 18 cases (26.5%). Sixty-three patients were evaluated PFS. The median PFS was 3.0 months. The median PFS of adenocarcinoma and non-adenocarcinoma was 3.0 months vs 2.6 months. The drug-related adverse reactions were</description><identifier>ISSN: 1009-3419</identifier><identifier>EISSN: 1999-6187</identifier><identifier>DOI: 10.3779/j.issn.1009-3419.2009.12.18</identifier><identifier>PMID: 20723391</identifier><language>chi</language><publisher>China: Chinese Anti-Cancer Association; Chinese Antituberculosis Association</publisher><subject>Erlotinib ; Lung neoplasms ; Treatment outcome</subject><ispartof>Zhongguo fei ai za zhi, 2009-12, Vol.12 (12), p.1309-1311</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902,36990</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20723391$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Yuhua</creatorcontrib><creatorcontrib>Tao, Hong</creatorcontrib><creatorcontrib>Tang, Junfang</creatorcontrib><creatorcontrib>Zhang, Xinyong</creatorcontrib><creatorcontrib>Zhu, Yunzhong</creatorcontrib><creatorcontrib>Liu, Zhe</creatorcontrib><creatorcontrib>Shi, Heling</creatorcontrib><creatorcontrib>Meng, Qiyi</creatorcontrib><creatorcontrib>Wu, Wei</creatorcontrib><creatorcontrib>Liu, Zan</creatorcontrib><creatorcontrib>Guo, Lili</creatorcontrib><creatorcontrib>Li, Mingzhi</creatorcontrib><creatorcontrib>Xu, Liyan</creatorcontrib><title>A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer.</title><title>Zhongguo fei ai za zhi</title><addtitle>Zhongguo Fei Ai Za Zhi</addtitle><description>Erlotinib is a small molecular inhibitor of tyrosine kinase. Multiple foreign and demestic studies have confirmed that it can prolong the median progression-free survival time (PFS) and the overall survival (OS), which could be more significant in the selected population. In this study we retrospectively oberserved the response, the survival and adverse reaction of erlotinib in non-selected non-small cell lung cancer. The retrospective study included seventy non-small-cell lung cancer patients, who were treated with erlotinib from July 2005 to July 2009. Erlotinib was prescribed at a dose of 150 mg daily. Sixty-eight patients were evaluated response. Among these patients, CR 0 case, PR 26 cases, RR (CR+PR) 38.2% and SD 24 cases as their best response, disease control rate (DCR=CR+PR+SD) 73.5%, PD 18 cases (26.5%). Sixty-three patients were evaluated PFS. The median PFS was 3.0 months. The median PFS of adenocarcinoma and non-adenocarcinoma was 3.0 months vs 2.6 months. The drug-related adverse reactions were</description><subject>Erlotinib</subject><subject>Lung neoplasms</subject><subject>Treatment outcome</subject><issn>1009-3419</issn><issn>1999-6187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNo9UMtOHDEQtKKgQDb5BWSJA6cZ_NqxfUQrCEirgAg5j_zoAa9mxovtScTfYwLk0l1dXapWF0InlLRcSn22a0POc0sJ0Q0XVLesopaylqpP6IhqrZuOKvm54g_JIfqa846QjmkuvqBDRiTjXNMj5M7xHZQU8x5cCX8A_yqLf8ZxwBdpjCXMweIw4_II-D6BKRPM5XUrCb41JdQp47-hPOKfcW7yZMYRb6CW7TI_4I2ZHaT2GzoYzJjh-3tfod-XF_ebq2Z78-N6c75tPNW0NINTilihCTFqbTh46xklbM08I6YTrjLUEOeptV4Qs5YdDFQRGKyyMAjJV-j6zddHs-v3KUwmPffRhP4fEdNDb1IJboQerJJ8cMJ4uha8xuIIZeCEZmA7SUT1On3z2qf4tEAu_RSyq5-ZGeKSeymU7pSqMa7Q8btysRP4_3c_MuYvXi6AaA</recordid><startdate>20091220</startdate><enddate>20091220</enddate><creator>Wu, Yuhua</creator><creator>Tao, Hong</creator><creator>Tang, Junfang</creator><creator>Zhang, Xinyong</creator><creator>Zhu, Yunzhong</creator><creator>Liu, Zhe</creator><creator>Shi, Heling</creator><creator>Meng, Qiyi</creator><creator>Wu, Wei</creator><creator>Liu, Zan</creator><creator>Guo, Lili</creator><creator>Li, Mingzhi</creator><creator>Xu, Liyan</creator><general>Chinese Anti-Cancer Association; Chinese Antituberculosis Association</general><scope>NPM</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20091220</creationdate><title>A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer.</title><author>Wu, Yuhua ; Tao, Hong ; Tang, Junfang ; Zhang, Xinyong ; Zhu, Yunzhong ; Liu, Zhe ; Shi, Heling ; Meng, Qiyi ; Wu, Wei ; Liu, Zan ; Guo, Lili ; Li, Mingzhi ; Xu, Liyan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d191t-fc880b4900a85a3edbd210252d20a64c3ed1a0cd1bbd40a576ef180efb8bef473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2009</creationdate><topic>Erlotinib</topic><topic>Lung neoplasms</topic><topic>Treatment outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Yuhua</creatorcontrib><creatorcontrib>Tao, Hong</creatorcontrib><creatorcontrib>Tang, Junfang</creatorcontrib><creatorcontrib>Zhang, Xinyong</creatorcontrib><creatorcontrib>Zhu, Yunzhong</creatorcontrib><creatorcontrib>Liu, Zhe</creatorcontrib><creatorcontrib>Shi, Heling</creatorcontrib><creatorcontrib>Meng, Qiyi</creatorcontrib><creatorcontrib>Wu, Wei</creatorcontrib><creatorcontrib>Liu, Zan</creatorcontrib><creatorcontrib>Guo, Lili</creatorcontrib><creatorcontrib>Li, Mingzhi</creatorcontrib><creatorcontrib>Xu, Liyan</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Zhongguo fei ai za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Yuhua</au><au>Tao, Hong</au><au>Tang, Junfang</au><au>Zhang, Xinyong</au><au>Zhu, Yunzhong</au><au>Liu, Zhe</au><au>Shi, Heling</au><au>Meng, Qiyi</au><au>Wu, Wei</au><au>Liu, Zan</au><au>Guo, Lili</au><au>Li, Mingzhi</au><au>Xu, Liyan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer.</atitle><jtitle>Zhongguo fei ai za zhi</jtitle><addtitle>Zhongguo Fei Ai Za Zhi</addtitle><date>2009-12-20</date><risdate>2009</risdate><volume>12</volume><issue>12</issue><spage>1309</spage><epage>1311</epage><pages>1309-1311</pages><issn>1009-3419</issn><eissn>1999-6187</eissn><abstract>Erlotinib is a small molecular inhibitor of tyrosine kinase. Multiple foreign and demestic studies have confirmed that it can prolong the median progression-free survival time (PFS) and the overall survival (OS), which could be more significant in the selected population. In this study we retrospectively oberserved the response, the survival and adverse reaction of erlotinib in non-selected non-small cell lung cancer. The retrospective study included seventy non-small-cell lung cancer patients, who were treated with erlotinib from July 2005 to July 2009. Erlotinib was prescribed at a dose of 150 mg daily. Sixty-eight patients were evaluated response. Among these patients, CR 0 case, PR 26 cases, RR (CR+PR) 38.2% and SD 24 cases as their best response, disease control rate (DCR=CR+PR+SD) 73.5%, PD 18 cases (26.5%). Sixty-three patients were evaluated PFS. The median PFS was 3.0 months. The median PFS of adenocarcinoma and non-adenocarcinoma was 3.0 months vs 2.6 months. The drug-related adverse reactions were</abstract><cop>China</cop><pub>Chinese Anti-Cancer Association; Chinese Antituberculosis Association</pub><pmid>20723391</pmid><doi>10.3779/j.issn.1009-3419.2009.12.18</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1009-3419
ispartof Zhongguo fei ai za zhi, 2009-12, Vol.12 (12), p.1309-1311
issn 1009-3419
1999-6187
language chi
recordid cdi_doaj_primary_oai_doaj_org_article_eb873fc4ad1543629c012ec492eb6704
source Publicly Available Content Database
subjects Erlotinib
Lung neoplasms
Treatment outcome
title A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer.
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T10%3A38%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Retrospective%20Study%20of%20Erlotinib%20in%20the%20Treatment%20of%2070%20Patients%20with%20Non-small%20Cell%20Lung%20Cancer.&rft.jtitle=Zhongguo%20fei%20ai%20za%20zhi&rft.au=Wu,%20Yuhua&rft.date=2009-12-20&rft.volume=12&rft.issue=12&rft.spage=1309&rft.epage=1311&rft.pages=1309-1311&rft.issn=1009-3419&rft.eissn=1999-6187&rft_id=info:doi/10.3779/j.issn.1009-3419.2009.12.18&rft_dat=%3Cproquest_doaj_%3E748968872%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d191t-fc880b4900a85a3edbd210252d20a64c3ed1a0cd1bbd40a576ef180efb8bef473%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=748968872&rft_id=info:pmid/20723391&rfr_iscdi=true